Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. ATyr Pharma, Inc.
  6. Summary
    LIFE   US0021202025

ATYR PHARMA, INC.

(LIFE)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
11/23/2021 11/24/2021 11/26/2021 11/29/2021 11/30/2021 Date
8.06(c) 8.1(c) 8.06(c) 7.91(c) 8.34(c) Last
373 428 218 993 50 814 150 812 315 835 Volume
+0.75% +0.50% -0.49% -1.86% +5.44% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 2,52 M - -
Net income 2021 -32,8 M - -
Net Debt 2021 - - -
P/E ratio 2021 -4,65x
Yield 2021 -
Sales 2022 4,22 M - -
Net income 2022 -40,7 M - -
Net Debt 2022 - - -
P/E ratio 2022 -4,93x
Yield 2022 -
Capitalization 232 M 232 M -
Capi. / Sales 2021 92,1x
Capi. / Sales 2022 55,0x
Nbr of Employees 42
Free-Float 97,7%
More Financials
Company
aTyr Pharma Inc is a United States-based biotechnology company. The Company engaged in the development of medicines based on biology. The CompanyÔÇÖs research and development efforts are concentrated on a new discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. 
More about the company
Ratings of aTyr Pharma, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
-
More Ratings
All news about ATYR PHARMA, INC.
11/30ATyr Pharma, Fujifilm Diosynth Biotechnologies Enter Manufacturing Agreement for ATYR19..
MT
11/30ATyr Pharma and FUJIFILM Diosynth Biotechnologies Announce Manufacturing Agreement for ..
AQ
11/15ATyr Pharma to Present at Upcoming Investor Conferences in November
AQ
11/12ATYR PHARMA INC Management's Discussion and Analysis of Financial Condition and Result..
AQ
11/12ATyr Pharma to Present at Upcoming Investor Conferences in November
AQ
11/11HC Wainwright Adjusts aTyr Pharma's Price Target to $11 from $18, Keeps Buy Rating
MT
11/10ATyr Pharma Announces Third Quarter 2021 Results and Provides Corporate Update - Form 8..
PU
11/10ATYR PHARMA : Q3 Earnings Snapshot
AQ
11/10ATyr Pharma Announces Third Quarter 2021 Results and Provides Corporate Update
AQ
11/10ATyr Pharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended ..
CI
11/09ATyr Pharma Presents Research Demonstrating Effects of Novel NRP2-Targeting Antibody, A..
AQ
11/09ATyr Pharma, Inc. Presents Research Demonstrating Effects of Novel NRP2-Targeting Antib..
CI
11/03ATyr Pharma to Webcast Conference Call Reporting Third Quarter 2021 Financial Results
AQ
10/12ATYR PHARMA : RBC Initiates aTyr Pharma at Outperform, Speculative Risk, Sets Price Target..
MT
10/11ATYR PHARMA : to Participate in Piper Sandler Investor Lung Day
AQ
More news
News in other languages on ATYR PHARMA, INC.
11/30ATyr Pharma et Fujifilm Diosynth Biotechnologies concluent un accord de fabrication pou..
09/17ATyr Pharma propose un prix de 8 dollars par action.
09/16Les actions du secteur de la santé sont largement absentes de la reprise des marchés ce..
09/16Les actions du secteur de la santé en baisse jeudi après-midi
09/15ATyr Pharma commence la vente d'actions - L'action chute de 9 % après les heures de nég..
More news
Analyst Recommendations on ATYR PHARMA, INC.
More recommendations
Chart ATYR PHARMA, INC.
Duration : Period :
aTyr Pharma, Inc. Technical Analysis Chart | LIFE | US0021202025 | MarketScreener
Technical analysis trends ATYR PHARMA, INC.
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 6
Last Close Price 8,34 $
Average target price 18,50 $
Spread / Average Target 122%
EPS Revisions
Managers and Directors
Sanjay S. Shukla President, Chief Executive Officer & Director
Jill M. Broadfoot Chief Financial Officer
John K. Clarke Chairman
Leslie Nangle Vice President-Research
Paul R. Schimmel Independent Director
Sector and Competitors
1st jan.Capi. (M$)
ATYR PHARMA, INC.114.95%232
MODERNA, INC.237.35%142 893
LONZA GROUP AG30.63%59 859
IQVIA HOLDINGS INC.44.63%49 504
SEAGEN INC.-8.64%29 257
CELLTRION, INC.-42.34%23 827